Interface Biologics

Develops transformative biomedical polymer technology to improve safety of med device. Focused on anti-thrombogenic additives and combo drug delivery devices.

[Interface Biologics @InterfaceBiolog]

Interface Biologics spins out Ripple Therapeutics to focus on Epidel #Drugdelivery #Ophthalmology #NewChemicalEntities https://t.co/kblw4KzGeE

[Interface Biologics @InterfaceBiolog]

Fresenius Medical Care has been granted FDA breakthrough device designation for their dialyzer formulated with Endexo® surface modification technology. #Dialysis #Biomaterials #Innovation

https://t.co/KE5g6PYafM

[Interface Biologics @InterfaceBiolog]

Our V.P. R&D @NaimarkWendy delivers Retinal Drug Delivery Solutions at OIS@ASRS 2019 #drugdelivery #ophthalmology #OIS #ASRS Watch here https://t.co/0u1RvBCTTL

[Evonik @Evonik]

#Evonik announced the acquisition of the Endexo® surface modification business of @InterfaceBiolog - a privately-held material science company located in Toronto, Canada - to further expand its #medicaldevice capabilities: https://t.co/ThwdvRN83L #biomaterials

[University of Toronto Entrepreneurship @UofTStartup]

🔬@InterfaceBiolog is acquired by @Evonik! Congratulations #UofT Prof. Paul Santerre & team.

“This is a professor’s dream. It's the best outcome for our startup: investment, sales & drawing a major company here to do product development.” https://t.co/vr7hhuEOAf #UofTStartup

[BioTuesdays @BioTuesdays]

This Week's Feature - @InterfaceBiolog sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform $ETK

Read the story - https://t.co/nqeS26CV5r

[Techna @technauhn]

Congratulations to Paul Santerre, TECHNA's Director of Research Faculty (Physical Sciences)!
His company Interface Biologics @InterfaceBiolog has sold their surface modification technology to @Evonik, a global chemical manufacturer.

[CRANIA @CRANIA_Toronto]

Meet Frank Shannon. He's the VP of clinical research, regulatory and quality affairs @InterfaceBiolog and a regulatory affairs advisor @H2i_UofT. At the #CRANIAconference, he will be running a workshop on how to navigate regulatory bodies. Register today ➡️https://t.co/rDI2EEZx2l

[Interface Biologics @InterfaceBiolog]

Interface Biologics Announces Sale of Endexo Surface Modification Business to @Evonik #MedicalDevice #Biomaterials

Read more: https://t.co/7wPNBytpOz

[Interface Biologics @InterfaceBiolog]

@InterfaceBiolog is currently seeking a Quality Specialist #biomaterials #Biotech #Jobs #Chemistry #DrugDelivery
https://t.co/cPeqXbmUJ0

[Interface Biologics @InterfaceBiolog]

@InterfaceBiolog is currently seeking a Research Scientist/Engineer #biomaterials #Biotech #Jobs #Chemistry #DrugDelivery

https://t.co/Aaa3NyMz9D

[Interface Biologics @InterfaceBiolog]

Link to @interfacebiolog poster from #AUA2019 - "In vitro evaluation of novel surface modifying molecules to prevent bacterial adhesion to urological devices" @lawsonresearch @WesternU #Urology #biomaterials #MedicalDevices
https://t.co/IFDgWbYyAY

[Interface Biologics @InterfaceBiolog]

"Pharmacokinetics and Pharmacodynamics of a Novel Dexamethasone Intravitreal Implant" @InterfaceBiolog Abstract Presented at #ARVO2019 available here: https://t.co/YB45I8fo6c
#Ophthalmology #DrugDelivery #Biomaterials

[Interface Biologics @InterfaceBiolog]

@InterfaceBiolog is in Chicago for #AUA2019 presenting on Endexo surface modified #urology catheters which reduce bacterial adhesion. Thanks to our collaborators @WesternU @lawsonresearch ! #biomaterials #medicaldevice
https://t.co/hUDitqj30h

[Interface Biologics @InterfaceBiolog]

@InterfaceBiolog to Present Local Drug Delivery Technology Update this Wednesday at Bloom Burton & Co. Healthcare Investor Conference #BBHIC2019 #Healthcare #Investment #DrugDelivery #Biomaterials #Ophthalmology
https://t.co/I2uNZOp7gS

[Research2Reality @r2rnow]

{New video} How can we make medical devices look invisible to blood cells that might otherwise clot on foreign surfaces? https://t.co/pPdX1VUMvI @uoft @uoftnews @uoftengineering @ibbme_uoft @researchuoft @InterfaceBiolog

[Interface Biologics @InterfaceBiolog]

The @InterfaceBiolog team will be at #ARVO2019 in Vancouver with Dr. Baruch Kuppermann who will be discussing our novel dexamethasone ocular implant! Presentation details in link.
#ophthalmology #biomaterials #drugdelivery
https://t.co/WOrpu0b32P

[Interface Biologics @InterfaceBiolog]

IBI is currently seeking a Research Scientist (Analytical) #Biomaterials #Biotech #Jobs https://t.co/RvOqqhqBg9

[Interface Biologics @InterfaceBiolog]

@InterfaceBiolog Announces New V.P., Business Development

https://t.co/ZrwUVzkUMs

[Interface Biologics @InterfaceBiolog]

Interface Biologics Completes Pre-IND Meeting with U.S. FDA on Epidel® Technology for treatment of Posterior Inflammatory Eye Diseases #drugdevelopment #drugdelivery #ophthalmology

https://t.co/MlU7ZUsE0L